| Company Name: |
InvivoChem |
| Tel: |
+1-708-310-1919 +1-13798911105 |
| Email: |
sales@invivochem.cn |
Vicagrel manufacturers
- Vicagrel
-
- $242.00
-
2026-04-20
- CAS:1314081-53-2
- Purity:
- Supply Ability: 10g
|
| | Vicagrel Basic information |
| Product Name: | Vicagrel | | Synonyms: | Vicagrel;Thieno[3,2-c]pyridine-5(4H)-acetic acid, 2-(acetyloxy)-α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-;methyl (S)-2-(2-acetoxy-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetate | | CAS: | 1314081-53-2 | | MF: | C18H18ClNO4S | | MW: | 379.86 | | EINECS: | | | Product Categories: | | | Mol File: | 1314081-53-2.mol |  |
| | Vicagrel Chemical Properties |
| Melting point | 73-75 °C | | Boiling point | 497.3±45.0 °C(Predicted) | | density | 1.347±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 250 mg/mL (658.14 mM) | | pka | 4.04±0.20(Predicted) | | form | Solid | | color | White to off-white |
| | Vicagrel Usage And Synthesis |
| Uses | Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease[1][2]. | | in vivo | Vicagrel (compound 9a) (oral, 3 mg/kg) has inhibitory effect on ADP-induced platelet aggregation in rats[1].
Vicagrel (oral, 1.14 mg/mL, 0-24 h) has giood preliminary pharmacokinetic with high bioavailability and low clinically effective dose[1].
Vicagrel (oral, 5 g/kg, single, for 14 days) has low dose-related toxicity in mouse[1]. | Animal Model: | Male Wistar rats[1]
(200250 g)
| | Dosage: | 3 mg/kg | | Administration: | oral | | Result: | Inhibitied platelet aggregation by ADP-induced in rats. |
| Animal Model: | SD male rats[1] | | Dosage: | 1.14 mg/mL | | Administration: | oral, 0-24 h | | Result: | Could be readily converted into clopidogrel thiolactone and had high bioavailability. |
| Animal Model: | Mice[1] | | Dosage: | 5 g/kg | | Administration: | oral, single, for 14 days | | Result: | Had very low acute toxicity. |
| | References | [1] French, et al. Method for preparing vicagrel. Patent. WO2014040498A1.
[2] Jiaqi Shan, et al. Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent. J Med Chem DOI:10.1021/jm300038c |
| | Vicagrel Preparation Products And Raw materials |
|